Agile Therapeutics (NASDAQ:AGRX)‘s stock had its “buy” rating reiterated by research analysts at Noble Financial in a research note issued on Wednesday.
Several other brokerages also recently commented on AGRX. HC Wainwright set a $8.00 price objective on shares of Agile Therapeutics and gave the company a “buy” rating in a research report on Thursday, December 28th. Cantor Fitzgerald reissued a “buy” rating and set a $8.00 price objective on shares of Agile Therapeutics in a research report on Monday, November 20th. William Blair downgraded shares of Agile Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, December 26th. Finally, Janney Montgomery Scott downgraded shares of Agile Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, December 22nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $9.00.
Shares of Agile Therapeutics (AGRX) opened at $3.19 on Wednesday. The firm has a market cap of $109.05, a PE ratio of -3.47 and a beta of 1.91. Agile Therapeutics has a 1 year low of $1.93 and a 1 year high of $5.60.
Hedge funds have recently made changes to their positions in the stock. Perceptive Advisors LLC bought a new position in Agile Therapeutics during the 4th quarter valued at about $9,092,000. Alyeska Investment Group L.P. bought a new position in Agile Therapeutics during the 3rd quarter valued at about $3,747,000. Broadfin Capital LLC bought a new position in Agile Therapeutics during the 4th quarter valued at about $964,000. Renaissance Technologies LLC lifted its stake in Agile Therapeutics by 313.7% during the 4th quarter. Renaissance Technologies LLC now owns 366,100 shares of the specialty pharmaceutical company’s stock valued at $985,000 after acquiring an additional 277,600 shares during the period. Finally, Russell Investments Group Ltd. bought a new position in Agile Therapeutics during the 3rd quarter valued at about $943,000. 67.34% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “Agile Therapeutics (AGRX) Stock Rating Reaffirmed by Noble Financial” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/03/16/agile-therapeutics-agrx-stock-rating-reaffirmed-by-noble-financial.html.
About Agile Therapeutics
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.